American Journal of Cardiology
Volume 104, Issue 8 , Pages 1063-1068 , 15 October 2009

Comparison of Prolonged Bivalirudin Infusion Versus Intraprocedural in Preventing Myocardial Damage After Percutaneous Coronary Intervention in Patients With Angina Pectoris

  • Bernardo Cortese, MD

      Affiliations

    • Interventional Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy
    • Corresponding Author InformationCorresponding author: Tel: +39-0564-483465; fax: +39-0564-483464
    • ,
  • Andrea Picchi, MD

      Affiliations

    • Interventional Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy
    • ,
  • Andrea Micheli, MD

      Affiliations

    • Interventional Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy
    • ,
  • Alberto Genovesi Ebert, MD

      Affiliations

    • Cardiology Department, Ospedale di Livorno, Livorno, Italy
    • ,
  • Francesca Parri

      Affiliations

    • Interventional Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy
    • ,
  • Silva Severi, MD

      Affiliations

    • Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy
    • ,
  • Ugo Limbruno, MD, PhD

      Affiliations

    • Interventional Cardiology Unit, Ospedale della Misericordia, Grosseto, Italy

Received 24 March 2009 ,Revised 3 June 2009 ,Accepted 3 June 2009.

References 

  1. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–863
  2. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907–919
  3. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216
  4. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–2230
  5. Bittl JA. Accounting for ACUITY. N Engl J Med. 2006;355:2249–2250
  6. Morrow DA. Antithrombotic therapy to support primary PCI. N Engl J Med. 2008;358:2280–2282
  7. Waksman R. ACUITY-PCI: one drug does not fit all. Lancet. 2007;369:881–882
  8. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease (Implications for patient selection). Circulation. 1990;82:1193–1202
  9. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J. 2008;156:44–56
  10. Jeremias A, Baim DS, Ho KK, Chauhan M, Carrozza JP, Cohen DJ, et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol. 2004;44:1210–1214
  11. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822–1828
  12. Cutlip DE, Kuntz RE. Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcome. Circulation. 2005;112:916–922
  13. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non–ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931–938
  14. Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2364–2373
  15. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–696
  16. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780–2783
  17. Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1406–1411
  18. Varani E, Balducelli M, Vecchi G, Gatti C, Lucchi GR, Maresta A. Occurrence of non-Q wave myocardial infarction following percutaneous coronary intervention in the stent era: systematic monitoring of the three markers of myocardial necrosis. J Interv Cardiol. 2005;18:243–248
  19. Matthews MA, Kunselman SJ, Gascho JA, Gilchrist IC. Differential release of cardiac enzymes after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2005;65:19–24
  20. Schofer J, Lampe F, Mathey DG, Muller-Hansen S, Voigt KD. Increase in creatine kinase and its MM isoforms after successful and uncomplicated coronary angioplasty. Z Kardiol. 1992;81:326–330
  21. Weitz JI, Bates SM. Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol. 2002;14(suppl B):2B–7B
  22. Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibatide on thrombin-induced platelet activation. Coron Artery Dis. 2006;17:471–476
  23. Prati F, Pawlowski T, Gil R, Labellarte A, Gziut A, Caradonna E, et al. Stenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: a major role of plaque embolization? (A serial intravascular ultrasound study). Circulation. 2003;107:2320–2325
  24. Uetani T, Amano T, Ando H, Yokoi K, Arai K, Kato M, et al. The correlation between lipid volume in the target lesion, measured by integrated backscatter intravascular ultrasound, and post-procedural myocardial infarction in patients with elective stent implantation. Eur Heart J. 2008;29:1714–1720
  25. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina (Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial). Circulation. 1995;92:727–733

PII: S0002-9149(09)01176-X

doi: 10.1016/j.amjcard.2009.06.005

American Journal of Cardiology
Volume 104, Issue 8 , Pages 1063-1068 , 15 October 2009

Article Tools

* Image Usage & Resolution